clinical application 1.dx exercise intolerance 1.1 vo 2 max vo 2 at 1.2 rer >1.2 (hrmax is not...

7
Clinical application 1. Dx exercise intolerance 1.1 VO 2 max VO 2 AT 1.2 RER >1.2 (HRmax is not achieved) 1.3 breathing reserve < 20% (N=20-40%) 1.4 SaO 2 1.5 V E /VO 2 (ventilatory equivalent for oxygen) > 40 2. Dx exercise-induced bronchospasm (EIB) 3. Aerobic fitness evaluation

Upload: gerald-chapman

Post on 22-Dec-2015

215 views

Category:

Documents


3 download

TRANSCRIPT

Page 1: Clinical application 1.Dx exercise intolerance 1.1  VO 2 max   VO 2 AT 1.2 RER >1.2 (HRmax is not achieved) 1.3  breathing reserve < 20% (N=20-40%)

Clinical application

1. Dx exercise intolerance1.1 VO2max VO2 AT

1.2 RER >1.2 (HRmax is not achieved)1.3 breathing reserve < 20% (N=20-40%)1.4 SaO2

1.5 VE/VO2 (ventilatory equivalent for oxygen) > 40

2. Dx exercise-induced bronchospasm (EIB)3. Aerobic fitness evaluation

Page 2: Clinical application 1.Dx exercise intolerance 1.1  VO 2 max   VO 2 AT 1.2 RER >1.2 (HRmax is not achieved) 1.3  breathing reserve < 20% (N=20-40%)

Research study

Optimal level of physical activity in children and adolescent with chronic lung disease

Page 3: Clinical application 1.Dx exercise intolerance 1.1  VO 2 max   VO 2 AT 1.2 RER >1.2 (HRmax is not achieved) 1.3  breathing reserve < 20% (N=20-40%)

Objectives

To study the optimal level of physical activity in children and adolescents with CLD

Page 4: Clinical application 1.Dx exercise intolerance 1.1  VO 2 max   VO 2 AT 1.2 RER >1.2 (HRmax is not achieved) 1.3  breathing reserve < 20% (N=20-40%)

Normal (n=18)

CLD (n=18)

Hx & PE

PFT

- Spirometry

- Lung volumes

- DLco

Exercise stress test

VO2 at AT correlate with physical activity

Experimental design

Page 5: Clinical application 1.Dx exercise intolerance 1.1  VO 2 max   VO 2 AT 1.2 RER >1.2 (HRmax is not achieved) 1.3  breathing reserve < 20% (N=20-40%)

Results

- Chronic interstitial lung 1

- Post lobectomy 5 - Pulmonary hemosiderosis 1 - Fibrotic lung 3

- BPD 2 - Asthma moderate persistent 6

Chronic lung diseases:

Page 6: Clinical application 1.Dx exercise intolerance 1.1  VO 2 max   VO 2 AT 1.2 RER >1.2 (HRmax is not achieved) 1.3  breathing reserve < 20% (N=20-40%)

Abnormal PFT

• Obstructive lung 7 (FEV1 80.0 +

12.9%pred)

• Restrictive lung 7 (TLC 63.7 + 12.5%pred)

• Diffusion defect 1 (DLco/VA = 77 %pred)

• Hyperinflation 9 (RV/TLC 38.9 + 6.5%pred)

Page 7: Clinical application 1.Dx exercise intolerance 1.1  VO 2 max   VO 2 AT 1.2 RER >1.2 (HRmax is not achieved) 1.3  breathing reserve < 20% (N=20-40%)

CLD(n = 18)

Control(n = 18)

P

FVC 77.3 + 22.6 97.9 + 12.5 0.002

FEV1 74.3 + 17.6 104.0 + 12.6 < 0.001

FEV1/FVC 83.4 + 12.7 90.1 + 3.8 0.047

FEF25-75% 49.9 + 23.1 75.6 + 18.6 0.001

TLC 82.8 + 18.6 95.6 + 9.8 0.015

RV/TLC 30.8 + 10.2 24.4 + 5.9 0.027

DLco/VA 113.2 + 27.3 109.1 + 30.3 0.671